一覧に戻る

タイトル	en Phase II Study of Gefitinib Readministration in Patients with Advanced Non-Small Cell Lung Cancer and Previous Response to Gefitinib
作成者	en Asahina, Hajime NRID 1000090374298 en Oizumi, Satoshi NRID 1000010421968 en Inoue, Akira en Kinoshita, Ichiro NRID 1000040343008 en Ishida, Takashi en Fujita, Yuka en Sukoh, Noriaki en Harada, Masao en Maemondo, Makoto en Saijo, Yasuo en Dosaka-Akita, Hirotoshi NRID 1000070222528 en Isobe, Hiroshi NRID 1000090241322 en Nukiwa, Toshihiro en Nishimura, Masaharu NRID 1000000208224
アクセス権	open access
権利情報	en Copyright © 2011 S. Karger AG, Basel
主題	Other en Epidermal growth factor receptor (EGFR) Other en Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Other en Gefitinib Other en Non-small cell lung cancer (NSCLC) Other en Chemotherapy Other en readministration NDC 493
内容注記	Abstract en Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We conducted the first prospective phase II study of gefitinib readministration in previous gefitinib responders. Methods: Gefitinib (250 mg/day) was readministered to patients with advanced/metastatic non-small cell lung cancer (NSCLC) who had achieved objective response to initial gefitinib and subsequently received cytotoxic chemotherapy after disease progression with initial gefitinib. The primary endpoint was the objective response rate with gefitinib readministration. Secondary endpoints were disease control rate, progression-free survival (PFS), overall survival (OS), quality of life ((QOL), and toxicity. Changes in lung cancer-related symptoms were evaluated using the seven-item lung cancer subscale of the questionnaire. Results: Sixteen patients were enrolled between February 2005 and January 2008. Most had received ≥ 3 regimens of chemotherapy. Response and disease-control rates for all patients were 0% and 44%. Median PFS and OS were 2.5 months and 14.7 months, respectively. Four of 7 patients with stable disease experienced a long duration (≥ 6 months) of disease control without severe toxicity. Symptom improvement was observed in 2 of 12 patients (17%) for whom QOL was evaluable. Conclusion: Gefitinib represents a useful therapeutic option for selected previous gefitinib responders.
出版者	en Karger
日付	Issued2011-04
言語	eng
資源タイプ	journal article
出版タイプ	AM
資源識別子	HDL http://hdl.handle.net/2115/45486
関連	isVersionOf DOI https://doi.org/10.1159/000326488 PMID 21474967
収録誌情報	PISSN 0030-2414 en Oncology : International Journal for Cancer Research and Treatment 巻79 号5-6 開始ページ423 終了ページ429
ファイル	fulltext Onc79-5-6_423-429.pdf 244.44 KB (application/pdf) Issued2011-04
コンテンツ更新日時	2023-07-26